• Merger Hamlet-SelectImmune
  • hamletpharma.com
  • selectimmune.com
    • Årsredovisningar
      • 20/21
      • 21/22
      • 22/23
Hamlet BioPharmaHamlet BioPharma
  • News
    • Press releases
    • Newsletters
    • Media Archive
    • Subscribe
    • Series of digital events
    • Commercial collaborations
  • Drug Development
    • Cancer
    • Infections
    • Tuberculosis
    • Our Pipeline
    • Publications
  • Contact us
  • Hamlet Biopharma
    • Patents
    • Board & Executive Team
  • Finance and Investor Relations
    • Financial Reports
    • Financial Calendar
    • General Meetings
    • The share
    • Spotlight Stock Market
    • Prospectus 2024
Press enter to begin your search
Category

Financial

Financial news

May 22 2025
Love0

Q3 Interim Report January – March 2025

By Hamlet Biopharma Financial, Press releases

   

Read More
Feb 13 2025
Love0

Q2 Interim Report October 2024 – December 2024

By Hamlet Biopharma Financial, Press releases

   

Read More
Nov 15 2024
Love0

Q1 Interim Report July 2024 – September 2024

By Hamlet Biopharma Financial, Press releases
Read More
Oct 31 2024
Love0

Hamlet BioPharma publicerar årsredovisning 2023/2024

By Hamlet Biopharma Financial, Press releases

Årsredovisningen för Hamlet BioPharma AB avseende verksamhetsåret 2023/2024 är nu publicerad och bifogad i detta meddelande.  

Read More
Aug 28 2024
Love0

Year-end Report (Q4) July 2023 – June 2024

By Hamlet Biopharma Financial, Press releases

   

Read More
May 24 2024
Love0

Q3 Interim Report January – March 2024

By Hamlet Biopharma Financial, Press releases
Read More
Feb 22 2024
Love0

Q2 Interim Report October – December 2023

By Hamlet Biopharma Financial, Press releases
Read More
Nov 23 2023
Love0

Hamlet BioPharma publicerar årsredovisning 2022/2023

By Hamlet Biopharma Financial, Press releases
Read More
Nov 17 2023
Love0

Q1 Interim report July – September 2023

By Hamlet Biopharma Financial, Press releases

English   Swedish

Read More

Related documents

  • Q1 Interim report Jul - Sep, 2023
  • Q1 Kvartalsrapport_Jul-Sep, 2023, Svenska

See all news →

Recent Posts

  • Q3 Interim Report January – March 2025 May 22, 2025
  • Hamlet BioPharma bjuder in till pressträff den 22 maj May 21, 2025
  • Vetenskapligt genombrott för Alpha1H:s verkningsmekanism i blåscancer May 19, 2025
  • Scientific Breakthrough in Alpha1H’s Mechanism of Action May 19, 2025
  • Hamlet BioPharma presenterar framgångsrika prekliniska och kliniska data för Alpha1H vid AACR 2025 – stärker positionen inom behandling av blåscancer May 2, 2025

hbp-logo

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.

Hamlet Biopharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958

Subscribe to receive newsletters

© 2025 Hamlet BioPharma.

  • News
    • Press releases
    • Newsletters
    • Media Archive
    • Subscribe
    • Series of digital events
    • Commercial collaborations
  • Drug Development
    • Cancer
    • Infections
    • Tuberculosis
    • Our Pipeline
    • Publications
  • Contact us
  • Hamlet Biopharma
    • Patents
    • Board & Executive Team
  • Finance and Investor Relations
    • Financial Reports
    • Financial Calendar
    • General Meetings
    • The share
    • Spotlight Stock Market
    • Prospectus 2024
  • Merger Hamlet-SelectImmune
  • hamletpharma.com
  • selectimmune.com
    • Årsredovisningar
      • 20/21
      • 21/22
      • 22/23

Hamlet Pharma AB

BMC D10
Klinikgatan 32
SE-222 42 Lund, Sweden
+46 40 12 25 00
info@hamletpharma.com

Swedish